{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:59:10Z","timestamp":1776790750419,"version":"3.51.2"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Technology Major Project of China","award":["2012-ZX09301003-001"],"award-info":[{"award-number":["2012-ZX09301003-001"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejphar.2018.01.041","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T02:42:52Z","timestamp":1517712172000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain"],"prefix":"10.1016","volume":"823","author":[{"given":"Xiaonan","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruibin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.01.041_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1212\/01.WNL.0000103237.62009.77","article-title":"Systemic lidocaine in pain due to peripheral nerve injury and predictors of response","volume":"62","author":"Attal","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2018.01.041_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40261-014-0259-1","article-title":"An investigation of factors contributing to higher levels of Placebo response in clinical trials in neuropathic pain: a systematic review and meta-analysis","volume":"35","author":"Arakawa","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejphar.2018.01.041_bib3","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1097\/01.j.pain.0000460358.01998.15","article-title":"Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?","volume":"156","author":"Attal","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pain.2005.10.036","article-title":"Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mouse","volume":"122","author":"Bourquin","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev.pa.20.040180.002301","article-title":"Efficient analysis of experimental observations","volume":"20","author":"Dixon","year":"1980","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(00)00276-1","article-title":"Spared nerve injury: an animal model of persistent peripheral neuropathic pain","volume":"87","author":"Decosterd","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1213\/01.ANE.0000131967.69309.4F","article-title":"Differential analgesic sensitivity of two distinct neuropathic pain models","volume":"99","author":"Decosterd","year":"2004","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejphar.2018.01.041_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrn3404","article-title":"The Na(V)1.7 sodium channel: from molecule to man","volume":"14","author":"Dib-Hajj","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2018.01.041_bib10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/neuonc\/nou048","article-title":"Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin","volume":"16","author":"Deuis","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(02)00039-8","article-title":"Pharmacological characterisation of the spared nerve injury model of neuropathic pain","volume":"98","author":"Erichsen","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1476-5381.2009.00437.x","article-title":"Subtype-selective targeting of voltage-gated sodium channels","volume":"158","author":"England","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pain.2011.09.008","article-title":"Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker","volume":"153","author":"Goldberg","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14728214.2014.915025","article-title":"Emerging drugs for neuropathic pain","volume":"19","author":"Gilron","year":"2014","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejphar.2018.01.041_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/13543784.16.5.635","article-title":"Voltage-gated Na+ channels in neuropathic pain","volume":"16","author":"Hargus","year":"2007","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2018.01.041_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/cn500171p","article-title":"No gain, no pain: NaV1.7 as an analgesic target","volume":"5","author":"King","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejphar.2018.01.041_bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/01.j.pain.0000460356.94374.a1","article-title":"World Health Organization (WHO) essential medicines lists: where are the drugs to treat neuropathic pain?","volume":"156","author":"Kamerman","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fphar.2015.00263","article-title":"Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes","volume":"6","author":"Laedermann","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib20","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1038\/ncomms9967","article-title":"Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7","volume":"6","author":"Minett","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2018.01.041_bib21","unstructured":"Newron reports serena trial top line results for ralfinamide: https:\/\/www.fiercebiotech.com\/biotech\/newron-reports-serena-trial-top-line-results-for-ralfinamide."},{"key":"10.1016\/j.ejphar.2018.01.041_bib22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.pain.2007.10.012","article-title":"Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice","volume":"137","author":"Nieto","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1472-6882-13-27","article-title":"Acute and chronic antihypertensive effects of Cinnamomum zeylanicum stem bark methanol extract in L-NAME-induced hypertensive rats","volume":"13","author":"Nyadjeu","year":"2013","journal-title":"BMC Complement. Altern. Med."},{"key":"10.1016\/j.ejphar.2018.01.041_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1744-8069-7-29","article-title":"Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice","volume":"7","author":"Renn","year":"2011","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00002508-200211000-00002","article-title":"Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy","volume":"18","author":"Schmader","year":"2002","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2005.01.030","article-title":"The anti-nociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons","volume":"510","author":"Stummann","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib27","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/s0304-3959(02)00183-5","article-title":"Anti-allodynic effect of NW-1029, a novel Na(+) channel blocker, in experimental animal models of inflammatory and neuropathic pain","volume":"102","author":"Veneroni","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nn.3602","article-title":"Regulating excitability of peripheral afferents: emerging ion channel targets","volume":"17","author":"Waxman","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2018.01.041_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.brainres.2015.08.010","article-title":"Changes in VGLUT2 expression and function in pain-related supraspinal regions correlate with the panesis of neuropathic pain in a mouse spared nerve injury model","volume":"1624","author":"Wang","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.01.041_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuint.2016.05.008","article-title":"Changes in VGLUT1 and VGLUT2 expression in rat dorsal root ganglia and spinal cord following spared nerve injury","volume":"99","author":"Wang","year":"2016","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2018.01.041_bib32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/FBP.0000000000000007","article-title":"The antinociceptive effects of intracerebroventricular administration of Chicago sky blue 6B, a vesicular glutamate transporter inhibitor","volume":"24","author":"Yu","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.01.041_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pain.2008.04.020","article-title":"Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat","volume":"139","author":"Zhang","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2018.01.041_bib34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1517\/13543771003774118","article-title":"Sodium channel blockers for neuropathic pain","volume":"20","author":"Zuliani","year":"2010","journal-title":"Expert. Opin. Ther. Pat."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918300530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918300530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T06:05:28Z","timestamp":1535090728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918300530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":34,"alternative-id":["S0014299918300530"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.01.041","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}